Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity

Vaccine

Volumn 29, Issue 43, 2011, Pages 7414-7423

  Liu, Genyan ^a,b   Yao, Kun ^a   Wang, Bing ^a   Zhou, Feng ^a   Chen, Yun ^a   Li, Linyun ^a   Chi, Jing ^a   Peng, Guangyong ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Epstein Barr virus; Heat shock protein 70; Immunotherapy; Latent membrane protein 2A

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HLA A2 ANTIGEN; LATENT MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME RECONSTITUTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; ANTIGENS, BACTERIAL; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; MYCOBACTERIUM TUBERCULOSIS; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 80053445033     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.063     Document Type: Article

References (45)

1. Cancer IAfRo Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. IARC Monogr Eval Carcinog Risks Hum 1997, 70:1-492.
2. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360(August (9331)):436-442.
3. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345(January (8941)):9-13.
4. Chen Y., Yao K., Wang B., Qing J., Liu G. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A). Cell Mol Immunol 2008, 5(October (5)):365-372.
5. Heussinger N., Buttner M., Ott G., Brachtel E., Pilch B.Z., Kremmer E., et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004, 203(June (2)):696-699.
6. Xu J.J., Yao K., Yu C.J., Chen X., Lu M.P., Sun H., et al. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells. Auris Nasus Larynx 2006, 33(December (4)):441-446.
7. Sun H., Yao K., Chen Y., Zhou F. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells. Chin Med J 2004, 117(October (10)):1558-1563.
8. Bollard C.M., Straathof K.C., Huls M.H., Leen A., Lacuesta K., Davis A., et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 2004, 27(July-August (4)):317-327.
9. Swanson-Mungerson M., Ikeda M., Lev L., Longnecker R., Portis T. Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases. J Antimicrob Chemother 2003, 52(August (2)):152-154.
10. Rickinson A.B., Moss D.J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997, 15:405-431.
11. Wang B., Yao K., Liu G., Xie F., Zhou F., Chen Y. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+T-cell epitopes. Cell Mol Immunol 2009, 6(April (2)):97-103.
12. Lee S.P., Thomas W.A., Murray R.J., Khanim F., Kaur S., Young L.S., et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993, 67(December (12)):7428-7435.
13. Lee S.P., Chan A.T., Cheung S.T., Thomas W.A., CroomCarter D., Dawson C.W., et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000, 165(July (1)):573-582.
14. Lautscham G., Haigh T., Mayrhofer S., Taylor G., Croom-Carter D., Leese A., et al. Identification of a TAP-independent, immunoproteasome-dependent CD8+T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol 2003, 77(February (4)):2757-2761.
15. Lee S.P, Tierney R.J., Thomas W.A., Brooks J.M., Rickinson A.B. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997, 158(April (7)):3325-3334.
16. Khanna R., Burrows S.R., Moss D.J., Silins S.L. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996, 70(August (8)):5357-5362.
17. Meij P., Leen A., Rickinson A.B., Verkoeijen S., Vervoort M.B., Bloemena E., et al. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 2002, 99(May (1)):93-99.
18. Straathof K.C.M., Bollard C.M., Popat U., Huls M.H., Lopez T., Morriss M.C., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005, 105(March (5)):1898-1904.
19. Bharadwaj M., Sherritt M., Khanna R., Moss D.J. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 2001, 19(27):3769-3777.
20. Lin C.-L., Lo W.-F., Lee T.-H., Ren Y., Hwang S.-L., Cheng Y.-F., et al. Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002, 62(December (23)):6952-6958.
21. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6(May (5)):404-414.
22. Taylor G.S., Haigh T.A., Gudgeon N.H., Phelps R.J., Lee S.P., Steven N.M., et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 2004, 78(January (2)):768-778.
23. Walker K.B., Keeble J., Colaco C. Mycobacterial heat shock proteins as vaccines-a model of facilitated antigen presentation. Curr Mol Med 2007, 7(June (4)):339-350.
24. Liu H., Wu B.H., Rowse G.J., Emtage P.C.R. Induction of CD4-independent E7-specific CD8+memory response by heat shock fusion protein. Clin Vaccine Immunol 2007, 14(August (8)):1013-1023.
25. Huang Q., Richmond J.F., Suzue K., Eisen H.N., Young R.A. In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent. J Exp Med 2000, 191(January (2)):403-408.
26. Liu G., Yao K., Wang B., Chen Y., Zhou F., Guo Y., et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein. Cell Mol Immunol 2009, 6(December (6)):423-431.
27. Redchenko I.V., Rickinson A.B. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol 1999, 73(January (1)):334-342.
28. Bollard C.M., Gottschalk S., Leen A.M., Weiss H., Straathof K.C., Carrum G., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110(October (8)):2838-2845.
29. Comoli P., Pedrazzoli P., Maccario R., Basso S., Carminati O., Labirio M., et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005, 23(December (35)):8942-8949.
30. Murray P.G., Constandinou C.M., Crocker J., Young L.S., Ambinder R.F. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998, 92(October (7)):2477-2483.
31. Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997, 186(October (8)):1315-1322.
32. Bendz H., Ruhland S.C., Pandya M.J., Hainzl O., Riegelsberger S., Brauchle C., et al. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem 2007, 282(October (43)):31688-31702.
33. Wan T., Zhou X., Chen G., An H., Chen T., Zhang W., et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 2004, 103(March (5)):1747-1754.
34. Rolland A. Gene medicines: the end of the beginning?. Adv Drug Delivery Rev 2005, 57(5):669-673.
35. Elliott S.L., Suhrbier A., Miles J.J., Lawrence G., Pye S.J., Le T.T., et al. Phase I trial of a CD8+T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008, 82(February (3)):1448-1457.
36. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunity. Trends Immunol 2001, 22(May (5)):269-276.
37. Mittendorf E.A., Holmes J.P., Murray J.L., von Hofe E., Peoples G.E. CD4+T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009, 9(January (1)):71-78.
38. Wong S.B.J., Bos R., Sherman L.A. Tumor-Specific CD4+T cells render the tumor environment permissive for infiltration by low-avidity CD8+T cells. J Immunol 2008, 180(March (5)):3122-3131.
39. Grange J.M., Bottasso O., Stanford C.A., Stanford J.L. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26(September (39)):4984-4990.
40. Tamura Y., Peng P., Liu K., Daou M., Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278(October (5335)):117-120.
41. Testori A., Richards J., Whitman E., Mann G.B., Lutzky J., Camacho L., et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008, 26(February (6)):955-962.
42. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365(June (9476)):2041-2054.
43. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31(3):164-172.
44. Ito Y., Kondo E., Demachi-Okamura A., Akatsuka Y., Tsujimura K., Tanimoto M., et al. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation. J Virol 2006, 80(January (2)):883-890.
45. Tao Q., Yang J., Huang H., Swinnen L.J., Ambinder R.F. Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol 2002, 160(May (5)):1839-1845.